We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+46.89%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$351M
(+27%)
Cap. Flow
+$70.1M
Cap. Flow
% of AUM
4.19%
Top 10 Holdings %
Top 10 Hldgs %
34.79%
Holding
547
New
45
Increased
181
Reduced
257
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$11.8M |
| 2 |
NVIDIA
NVDA
|
+$8.71M |
| 3 |
Apple
AAPL
|
+$8.26M |
| 4 |
SNDK
Sandisk
SNDK
|
+$7.29M |
| 5 |
Marvell Technology
MRVL
|
+$5.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Gold Trust
IAU
|
+$8.15M |
| 2 |
SPDR Gold Trust
GLD
|
+$7.23M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
+$6.88M |
| 4 |
AstraZeneca
AZN
|
+$5.05M |
| 5 |
British American Tobacco
BTI
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 47.74% |
| 2 | Healthcare | 19.17% |
| 3 | Communication Services | 9.91% |
| 4 | Consumer Discretionary | 7.67% |
| 5 | Consumer Staples | 3.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Arvinas
ARVN
$534M
| $85.3K | 0.01% |
10,269
-4,681
| -31% | -$43.7K |
|
427
Aquestive Therapeutics
AQST
$469M
| $83.1K | 0.01% |
19,965
-1,685
| -8% | -$7.09K |
|
428
Pacific Biosciences
PACB
$426M
| $83K | 0.01% |
49,432
-4,160
| -8% | -$6.05K |
|
|
EPRX
429
Eupraxia Pharmaceuticals
EPRX
$400M
| $82.6K | ﹤0.01% |
12,500
+2,500
| +25% | +$17.2K |
|
430
C4 Therapeutics
CCCC
$406M
| $82.2K | ﹤0.01% |
17,597
+281
| +2% | +$961 |
|
|
SLN
431
Silence Therapeutics
SLN
$569M
| $82.1K | ﹤0.01% |
7,475
-860
| -10% | -$6.05K |
|
|
IVA
432
Inventiva
IVA
$1.07B
| $81.6K | ﹤0.01% |
21,600
+5,600
| +35% | +$26.9K |
|
433
Prothena Corp
PRTA
$459M
| $81.6K | ﹤0.01% |
8,332
-1,221
| -13% | -$12.1K |
|
434
Cabaletta Bio
CABA
$448M
| $80.7K | ﹤0.01% |
25,950
+8,867
| +52% | +$29.2K |
|
435
Equillium
EQ
$161M
| $80K | ﹤0.01% |
+25,000
| New | +$59.9K |
|
436
Neurogene
NGNE
$691M
| $79.1K | ﹤0.01% |
2,515
-234
| -9% | -$6.44K |
|
437
Option Care Health
OPCH
$3.45B
| $75.5K | ﹤0.01% |
3,600
+2,000
| +125% | +$46.5K |
|
438
Sagimet Biosciences
SGMT
$460M
| $75.3K | ﹤0.01% |
9,738
+4,237
| +77% | +$28.8K |
|
439
Evolus
EOLS
$404M
| $72.7K | ﹤0.01% |
10,481
-1,022
| -9% | -$6.03K |
|
|
LKFT
440
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
| $71.7K | ﹤0.01% |
2,393
-238
| -9% | -$6.76K |
|
441
Establishment Labs
ESTA
$2.7B
| $68.6K | ﹤0.01% |
+800
| New | +$57.5K |
|
442
Dentsply Sirona
XRAY
$2.64B
| $67.9K | ﹤0.01% |
6,400
+2,800
| +78% | +$30.6K |
|
443
Enanta Pharmaceuticals
ENTA
$375M
| $67.5K | ﹤0.01% |
4,628
-522
| -10% | -$7.02K |
|
444
Kamada
KMDA
$400M
| $67.4K | ﹤0.01% |
9,181
-1,055
| -10% | -$8.33K |
|
445
Puma Biotechnology
PBYI
$409M
| $65.7K | ﹤0.01% |
8,101
-927
| -10% | -$6.79K |
|
446
Immuneering
IMRX
$283M
| $63.9K | ﹤0.01% |
12,797
+1,339
| +12% | +$6.77K |
|
447
Invivyd
IVVD
$178M
| $63.2K | ﹤0.01% |
72,487
+3,309
| +5% | +$4.15K |
|
448
Eledon Pharmaceuticals
ELDN
$276M
| $63K | ﹤0.01% |
+16,000
| New | +$58.2K |
|
|
PTHS
449
Pelthos Therapeutics
PTHS
$95.4M
| $61K | ﹤0.01% |
+2,160
| New | +$55.4K |
|
|
UPB
450
Upstream Bio Inc
UPB
$346M
| $59.9K | ﹤0.01% |
8,661
-929
| -10% | -$7.78K |
|
Similar funds
HA
TFS
GC
PA
JPM
NRI
CPO
LCI
China Universal Asset Management Company's Q2 2026 Portfolio in Review
As of Q2 2026, China Universal Asset Management Company held 547 positions worth $1.67B, up 27% from $1.32B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
China Universal Asset Management Company deployed $70.1M of net new capital in Q2 2026, opening 45 new positions and adding to 181 existing holdings. Its largest new stake was Onto Innovation: 10,200 shares worth $3.86M.
By sector, the portfolio is most concentrated in Technology at 48% of assets, up from 35% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was iShares Gold Trust, an estimated $8.15M trimmed.
- China Universal Asset Management Company's largest Q2 2026 buy was Onto Innovation: 10,200 shares worth $3.86M.
- China Universal Asset Management Company added most to Amazon in Q2 2026, an estimated $11.8M increase.
- China Universal Asset Management Company's biggest Q2 2026 reduction was iShares Gold Trust, cutting an estimated $8.15M.
- China Universal Asset Management Company fully exited AstraZeneca in Q2 2026, selling an estimated $5.05M.
- China Universal Asset Management Company's ten largest holdings make up 35% of its $1.67B portfolio in Q2 2026.
- China Universal Asset Management Company opened 45 new positions and closed 36 in Q2 2026.
- China Universal Asset Management Company's portfolio value rose 27% quarter-over-quarter to $1.67B.
Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.